We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.26 | 0.60% | 43.71 | 2,352 | 10:15:34 |
From May 2019 to May 2024
By Tapan Panchal
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday it has embarked on a new study to evaluate the effects of losmapimod medicine in patients with acute coronary syndrome.
The syndrome is a term for various heart conditions including heart attacks, where there is an abrupt reduction of blood flow to the heart through the coronary arteries.
The pharmaceutical company said that it has started a phase III study to assess whether losmapimod can reduce the risk of a subsequent cardiac events when administered orally twice a day for a period of three months.
Shares of GSK at 1356 GMT were up 0.03% at 1582 pence, valuing the company at 76.78 billion pounds (128.49 billion).
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
